21.48 0.00 (0.00%)
After hours: 4:49PM EDT
|Bid||21.43 x 1200|
|Ask||21.60 x 1400|
|Day's Range||21.03 - 21.74|
|52 Week Range||19.36 - 45.16|
|Beta (3Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
DUBLIN, Sept. 13, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced the appointment of two new independent directors, Richard Gaynor, M.D. and Frank Anders (Andy) Wilson, to the company's Board of Directors. The company also announced the retirement of Floyd Bloom, M.D., a pioneer in the field of neuroscience who contributed immensely to the legacy of innovation and scientific excellence that remains core to Alkermes' mission today. Dr. Gaynor, who currently serves as the President of Research & Development at Neon Therapeutics, brings 18 years of experience in oncology-focused industrial drug development in addition to a distinguished career in academic medicine.
Alkermes plc (ALKS) and Biogen Inc. (BIIB) today announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of diroximel fumarate, an investigational, novel oral fumarate with a distinct chemical structure, for relapsing-remitting multiple sclerosis (RRMS), compared to TECFIDERA® (dimethyl fumarate).
Under the agreement, the parties agreed to request termination of the IPR and Alkermes granted Amneal the non-exclusive right to market a generic formulation of VIVITROL in the U.S. beginning sometime in 2028 or earlier under certain circumstances. Additional terms of the agreement are confidential.
-- Second Quarter Revenues of $279.9 Million , Primarily Driven by Approximately 24% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.27 and Non-GAAP ...
DUBLIN , July 18, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Thursday, July 25, 2019 , to discuss the company's ...
DUBLIN, July 15, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today provided an update on its regulatory strategy for ALKS 3831 (olanzapine/samidorphan), the company's investigational, novel, once-daily, oral atypical antipsychotic drug candidate designed to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain. Following a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA), the company plans to expand the NDA for ALKS 3831 to encompass the treatment of bipolar I disorder in addition to the treatment of schizophrenia.
WALTHAM, Mass., July 1, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced that for the 11th consecutive year, employees took a day out of the office to roll up their sleeves and volunteer with community organizations across the Greater Boston area as part of what was the company's largest-ever annual day of service – Alkermes in Action. On Thursday, June 27, more than 450 Alkermes employees volunteered to work on various activities supporting 15 local nonprofits that are aligned with the company's values as a corporate citizen.
-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage -- -- Proof-of-Mechanism Demonstrated by Desired Expansion of Tumor-Killing Immune ...
Biogen Inc. (BIIB) announced today new interim data from the ongoing open-label, pivotal EVOLVE-MS-1 study indicate that the investigational treatment diroximel fumarate was generally well tolerated in people with relapsing multiple sclerosis (MS). Diroximel fumarate, a novel oral fumarate candidate in development with Alkermes plc (ALKS), is under review with the U.S. Food and Drug Administration with a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019.
-- New Safety and Tolerability Data to Be Presented From ALPINE Study of ARISTADA® and INVEGA SUSTENNA® in Patients With Schizophrenia -- DUBLIN , May 22, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) ...
DUBLIN , May 14, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Senior Vice President of Corporate Planning, Blair Jackson , will participate in a fireside chat at the UBS Global ...
-- Clinical Data and Health Economics and Outcomes Research to be Presented May 18-22, 2019 at APA and ISPOR Annual Meetings -- DUBLIN , May 13, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today ...
-- First Quarter Revenues of $223.1 Million , Primarily Driven by ~8% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.62 and Non-GAAP Net Loss ...
NEW YORK, NY / ACCESSWIRE / April 25, 2019 / Alkermes Plc (NASDAQ: ALKS ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 25, 2019 at 8:30 AM Eastern ...
DUBLIN, April 24, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced that C. Todd Nichols, an executive with more than two decades of extensive commercial experience in the biopharmaceutical sector, will become the company's Senior Vice President of Sales and Marketing effective May 13, 2019. He will serve on the Alkermes executive management team and report to Richard Pops, the company's Chief Executive Officer. Mr. Nichols most recently held the position of Vice President, Marketing and Sales, Inflammation and Immunology at Celgene, where he was responsible for developing and managing all aspects of U.S. commercial planning, brand P&L, strategy development, go-to-market modeling and launch execution for ozanimod. "I am excited to join a company with strong leadership, dedicated employees and that is rooted in its mission to make a positive impact on patients struggling with central nervous system (CNS) disorders," said Mr. Nichols.
DUBLIN , April 18, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, Apr. 25, 2019 , to discuss the company's ...
-- Large, randomized ALPINE trial showed both long-acting injectable medications effectively controlled schizophrenia symptoms throughout six-month study -- -- ARISTADA demonstrated significant and similar ...
DUBLIN, April 8, 2019 /PRNewswire/ -- Alkermes plc (ALKS) announced today that Jim Robinson, President and Chief Operating Officer, has resigned from his position and will leave the company, effective April 19, 2019, for personal reasons. "The past year has been incredibly rewarding and I am honored to have had the opportunity to work for an organization so committed to making an impact for patients struggling with serious mental illness and addiction," said Jim Robinson. "On behalf of the Alkermes team, I would like to thank Jim for his contributions, and I wish him well in his future endeavors," said Richard Pops, Chief Executive Officer.
DUBLIN, April 3, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced the next evolution of the ALKERMES PATHWAYS RESEARCH AWARDSSM program, an initiative designed to support the next generation of researchers who are working on the front lines to advance understanding and awareness of central nervous system (CNS) disorders. The program will continue to support projects focused on helping those living with substance use disorders (SUDs) and is expanding to include projects dedicated to helping people living with schizophrenia. "The Pathways program exemplifies our company's commitment to helping researchers find unique and meaningful ways to impact the people and communities we serve with our medicines," said Craig Hopkinson, M.D., Chief Medical Officer and Senior Vice President of Medicines Development and Medical Affairs at Alkermes.
-- Company to Host Investor Conference Call at 8:00 a.m. ET on Friday, April 12 -- -- Poster Presentations to Highlight New Data on ARISTADA® and ALKS 3831 -- DUBLIN , April 1, 2019 /PRNewswire/ -- Alkermes ...
Group Aims to Bring Disease-Associated Biomarker Through FDA’s Drug Development Tools Qualification Program
DUBLIN , March 5, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Cowen and Company 39 th Annual Health Care Conference on ...
NEW YORK, Feb. 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
DUBLIN, Feb. 26, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced the initiation of ARTISTRY-2, a new clinical study of ALKS 4230 administered subcutaneously as monotherapy and in combination with the PD-1 inhibitor KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. The study will explore the safety, tolerability and efficacy of ALKS 4230 administered subcutaneously and assess once-weekly and once-every-three-week dosing schedules.